ID   U3065MG
AC   CVCL_IR87
SY   U3065-MG; U3065
DR   cancercelllines; CVCL_IR87
DR   GEO; GSM1857598
DR   GEO; GSM1857814
DR   GEO; GSM2368449
DR   GEO; GSM2368530
DR   GEO; GSM2368533
DR   GEO; GSM2369073
DR   Progenetix; CVCL_IR87
DR   Wikidata; Q54973716
RX   PubMed=26629530;
RX   PubMed=27689322;
RX   PubMed=27974212;
RX   PubMed=28122246;
WW   http://www.hgcc.se/
CC   Part of: Human Glioblastoma Cell Culture (HGCC) resource.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): PubMed=26629530; PubMed=27974212
ST   Amelogenin: X,Y
ST   CSF1PO: 10,13
ST   D13S317: 8,10
ST   D16S539: 11,12
ST   D18S51: 12,15
ST   D19S433: 13
ST   D21S11: 28,30.2
ST   D2S1338: 19,21
ST   D3S1358: 16,17
ST   D5S818: 11
ST   D7S820: 8,11
ST   D8S1179: 14,15
ST   FGA: 21,25
ST   TH01: 9.3
ST   TPOX: 8,12
ST   vWA: 14,16
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   77Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 8
//
RX   PubMed=26629530; DOI=10.1016/j.ebiom.2015.08.026;
RA   Xie Y., Bergstrom T., Jiang Y.-W., Johansson P., Marinescu V.D.,
RA   Lindberg N., Segerman A., Wicher G., Niklasson M., Baskaran S.,
RA   Sreedharan S., Everlien I., Kastemar M., Hermansson A., Elfineh L.,
RA   Libard S., Holland E.C., Hesselager G., Alafuzoff I., Westermark B.,
RA   Nelander S., Forsberg-Nilsson K., Uhrbom L.;
RT   "The Human Glioblastoma Cell Culture resource: validated cell models
RT   representing all molecular subtypes.";
RL   EBioMedicine 2:1351-1363(2015).
//
RX   PubMed=27689322; DOI=10.18632/oncotarget.12298;
RA   Schmidt L., Baskaran S., Johansson P., Padhan N., Matuszewski D.J.,
RA   Green L.C., Elfineh L., Wee S.-M., Haggblad M., Martens U.,
RA   Westermark B., Forsberg-Nilsson K., Uhrbom L., Claesson-Welsh L.,
RA   Andang M., Sintorn I.-M., Lundgren B., Lonnstedt I., Krona C.,
RA   Nelander S.;
RT   "Case-specific potentiation of glioblastoma drugs by pterostilbene.";
RL   Oncotarget 7:73200-73215(2016).
//
RX   PubMed=27974212; DOI=10.1016/j.celrep.2016.11.056;
RA   Segerman A., Niklasson M., Haglund C., Bergstrom T., Jarvius M.,
RA   Xie Y., Westermark A., Sonmez D., Hermansson A., Kastemar M.,
RA   Naimaie-Ali Z., Nyberg F., Berglund M., Sundstrom M., Hesselager G.,
RA   Uhrbom L., Gustafsson M., Larsson R., Fryknas M., Segerman B.,
RA   Westermark B.;
RT   "Clonal variation in drug and radiation response among
RT   glioma-initiating cells is linked to proneural-mesenchymal
RT   transition.";
RL   Cell Rep. 17:2994-3009(2016).
//
RX   PubMed=28122246; DOI=10.1016/j.celrep.2017.01.003;
RA   Jiang Y.-W., Marinescu V.D., Xie Y., Jarvius M., Maturi N.P.,
RA   Haglund C., Olofsson S., Lindberg N., Olofsson T., Leijonmarck C.,
RA   Hesselager G., Alafuzoff I., Fryknas M., Larsson R., Nelander S.,
RA   Uhrbom L.;
RT   "Glioblastoma cell malignancy and drug sensitivity are affected by the
RT   cell of origin.";
RL   Cell Rep. 18:977-990(2017).
//